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Aims: The aim of this study was to compare the efficacy and tolerability of BP-C1 vs equal-
looking placebo in metastatic breast cancer.
Materials and methods: A randomized, double-blind, placebo-controlled multi-center study 
with a semicross-over design was performed. Sixteen patients received daily intramuscular 
injection of 0.035  mg/kg bodyweight of BP-C1 and 15 patients received equal-looking placebo 
for 32 days. After 32 days, the placebo patients crossed to BP-C1 with the last observation 
in the placebo period as baseline. The status of receptors including estrogen receptor (ER), 
progesterone receptor (PtR), and human EGF receptor 2 (HER2) was analyzed prior to inclu-
sion in the study. Thoracoabdominal CT scan was blindly analyzed by the same independent 
radiologist in accordance with the RECIST criteria 1.1. Toxicity was assessed according to the 
NCI Bethesda Version 2.0 (CTC-NCI), and the quality of life (QOL) was assessed according to 
European Organization for the Research and Treatment of Cancer QOL-C30 and QOL-BR23.
Results: The sum of target lesion diameters (sum lesions) after 32 days of treatment increased 
by 8.9% (P=0.08) in the BP-C1 arm compared to 37.6% (P<0.001) in placebo patients. Twelve 
of the 15 placebo patients subsequently had BP-C1 treatment. The increase in sum lesions was 
3.5% in these patients. The sum of CTC-NCI was increased 18.7% in the BP-C1 arm (P=0.38) 
compared to 50.9% (P=0.04) in placebo patients. Four mild/moderate adverse events (AEs) 
present in BP-C1. Two mild/moderate AEs and one severe AE present in placebo. The QOL 
benchmarks “breast cancer problems last week”, “sexual interest and activity last 4 weeks”, 
and “breast cancer-related pain and discomfort last week” were stable in the BP-C1 arm but 
deteriorated in placebo patients. The sum lesions increased significantly in ER+ (P=0.02) and 
PtR+ (P=0.03) but not in HER2+. The increase in sum lesions significantly decreased (P=0.02) 
with an increasing number of negative receptors.
Conclusion: A total of 32 days of BP-C1 treatment inhibited cancer growth and was well toler-
ated with few and mainly mild AEs. The efficacy of BP-C1 was superior in receptor-negative 
patients.
ClinicalTrials.gov Identifier: NCT03603197.
Keywords: benzene-polycarboxylic acid complex, BP-C1, low-dose cisplatin, breast cancer, 
stage IV, hormone receptors, randomized double-blind
Introduction
A major improvement in the prognosis of breast cancer has occurred during the last 
few decades, including a median reduction in the breast cancer mortality of 19% due 
to novel adjuvant agents and early detection.1,2 However, the median overall survival in 
metastatic breast cancer (MBC) is ~3 years and the 5-year survival is only 25%.3,4 These 
figures have not improved substantially, and MBC is still the leading cause of cancer-
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related deaths in females worldwide.1 Findings indicate that 
improvement in adjuvant treatment of breast cancer induces 
a negative selection over time to more unfavorable patient 
characteristics in recent cohorts in those patients who actu-
ally develop metastases. This may account for the unchanged 
outcome of treatment of MBC patients.5 While some women 
with MBC may achieve long-term survival, the therapeutic 
aim is palliation, balancing treatment efficacy in terms of the 
delayed progression of the disease and prolonged survival to 
drug-induced toxicity and AEs because maintaining QOL as 
long as possible is crucial.
The selection of MBC treatment is guided by patients’ 
choices, age, menopausal and hormone receptor status, 
disease-related symptoms, burden of metastases, toxicity, 
comorbid conditions, and prior treatment history.6 Addition-
ally, the human EGF receptor 2 (HER2) expression is often 
taken into account. Surgery, radiation, hormonal therapy, 
and chemotherapy in addition to immunotherapy and gene 
therapy are the most common treatments for MBC.7 Che-
motherapy is considered as the first choice of treatment in 
women who rapidly develop progressive visceral metastasis 
or have hormone receptor-negative disease or resistance to 
endocrine therapy.7 However, systemic chemotherapy has 
less impact with age, severe side effects, and poor response 
and seldom improves survival substantially. Triple-negative 
breast cancer (TNBC) is a particular therapeutic challenge. 
Cytotoxic chemotherapy remains the mainstay of treatment 
as data from many studies have shown a benefit in the neo-
adjuvant, adjuvant, and metastatic settings.8–10 The TNBC 
paradox refers to a higher response to chemotherapy in TNBC 
patients compared to those with other breast cancer types in 
spite of the general poor prognosis of TNBC.11
The role of platinum-based compounds in the treatment 
of MBC has been extensively studied. Cisplatin and carbo-
platin are active in previously untreated patients with MBC 
with mean response rates 50% and 32%, respectively, but 
the response rate of platinum monotherapy in pretreated 
patients declines markedly to <10%.12 In addition, platinum 
treatment is hampered by serious systemic toxicities and drug 
resistance and the pharmacokinetics of most platinum drugs 
are largely unknown.13
In order to develop and provide MBC patients a cost-
effective treatment with minimal toxicity, a new agent, 
BP-C1, that is also suitable for the treatment of MBC in 
the third world, has been introduced.14 BP-C1 contains a 
benzene-poly-carboxylic acid complex with cis-diammin-
eplatinum (II) dichloride, inducing apoptosis in human 
breast cancer cells.15 Previous studies with BP-C1 in the 
treatment of MBC patients have shown that tumor growth 
decreased without causing extra toxicity,14,16 although 
mainly manageable mild-to-moderate transient side effects 
may occur.
The primary aim of the present study was to compare the 
palliative efficacy and tolerability of BP-C1 with a placebo 
during 32 days of continuous treatment of patients suffering 
from pre-treated MBC. The secondary aim was to analyze 
if the efficacy of BP-C1 was related to the receptor status of 
the patients in a subset analysis.
Materials and methods
The Ethical Committee of the Institute for Development of 
Human Research in Thailand approved the study on June 
17, 2013. All patients gave their written informed consent 
to participate before being included in the study. The author 
and the co-authors have completed the conflict of interest 
form and ensured that no such conflict exists.
The study population consisted of female patients 
between the age of 18 and 80 years, suffering from histologi-
cally verified MBC with measurable metastases, who had 
previously undergone at least two lines of chemotherapy and 
had an expected survival time of at least 3 months.
Patients with bilirubin >34 µmol/L or Alain aminotrans-
ferase (ALAT) more than three times the upper limit of nor-
mal range, serum creatinine >120 µmol/L, Hgb <6.0  mmol/L, 
platelet count <100,000/mm3, or leucocytes <3×109/L or who 
had an abnormal coagulation capacity were excluded from 
the study. Additionally, patients with verified brain metastasis, 
synchronous cancer, clinically significant abnormal ECG, or 
a Karnofsky score of <60% were excluded. Finally, patients 
under systemic treatment with corticosteroids or other immu-
nosuppressive drugs the previous 21 days and patients with 
uncontrolled bacterial, viral, fungal, or parasite infection 
were excluded from the study population.
The study sample consisted of 31 patients from 4 of 
the 11 territorial Thai cancer hospitals (Table 1). By block 
randomization, 16 patients were allocated to BP-C1 and 15 
patients were allocated to an equal-looking placebo treatment 
for 32 days. Twelve of the 15 patients allocated to placebo 
had BP-C1 after finalizing the placebo period. Due to rapid 
disease progression, the remaining three patients were with-
drawn from the study and had terminal care.
The general condition was “good” or “very good” in most 
of the patients at baseline. Two patients in the BP-C1 group 
and three patients in the placebo group were classified as 
“fair”. The two groups were comparable with regard to all 
the initially recorded baseline characteristics, previous cancer 
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treatments, and clinical findings. The study was carried out 
between June 2014 and August 2016.
Design and randomization
The first part of the study was performed as a randomized, 
double-blind, and placebo-controlled multi-center trial with 
a stratified semicross-over design.17 The stratification factors 
were age and hospital site. The three age strata were as fol-
lows: ≤45, 46–60, and ≥60 years. The patients within each 
stratum were allocated 1:1 to BP-C1 or an equal-looking 
placebo by block randomization with random block size 
between four and eight.18 A total of 1  mL of the placebo con-
sisted of caramel color E150a (12.5 mg) diluted in an isotonic 
solution. The randomization code was broken after 32 days, 
and the patients allocated to placebo then had BP-C1 for an 
additional 32 days of treatment. The baseline for this group 
after reallocation was the last observation before changing 
to BP-C1. The patients allocated to BP-C1 by randomization 
together with the patients later changed to BP-C1 form the 
joint BP-C1 group. The second part of the study was an open-
label multi-center trial in this joint BP-C1 group.
Main variables were percentage change in the sum of 
diameters of up to five of the largest target lesions (sum 
lesions) measured by CT using the RECIST criteria 1.1. After 
32 days of treatment, the patients were classified according 
to the RECIST criteria as complete responder (CR), partial 
responder (PR), stable disease (SD), or progressive disease 
(PD). The Toxicity Criteria NCI Bethesda (CTC-NCI) Version 
2.0 was used for the measurement of the tolerability. The sum 
of CTC score and the maximum score (max CTC) were used 
as variables. The QOL was recorded by using QLQ-C30 and 
QLQ-BR23 from the European Organization for the Research 
and Treatment of Cancer. The QOL variables were developed 
from the QOL questionnaires, as recommended. The sum of 
scores within each of the three parts in the two questionnaires 
QLQ-C30 and QLQ-BR23 resulted in three variables. The 
three sum of scores obtained from QOL-C30 are questions 
C1–C5 “physical activity problems”, questions C6–C28 
“discomfort last week”, and questions C29–C30 “health and 
life quality”. From QOL-BR23, the developed variables were 
questions BR1–BR13 “problems related to the breast cancer 
treatment last week”, questions BR14–BR16 “sexual interest 
and activity last 4 weeks”, and questions BR17–BR 23 “breast 
cancer-related pain and discomfort last week”.
Study procedures
Patients fulfilling the criteria for participation and having 
given their written consent to participate were entered into 
a screening phase of maximum 21 days. Laboratory screen-
ing was performed in order to ensure the exclusion criteria, 
and samples for the receptor status were taken. Estrogen 
receptor (ER), progesterone receptor (PtR), and HER2 were 
recorded as positive (+) or negative (–). It is ER-alfa and PR 
A-form given. During the screening phase, thoracoabdominal 
CT scans were performed, and in case of suspected bone or 
brain metastases, an MRI was taken. Additionally, CTC-NCI, 
QLQ-C30, and QLQ-BR23 were recorded by the patients. 
Each patient was given an identification number, hiding the 
treatment randomization code. The trial injections started on 
Day 1, and the patients received one daily Intramuscularly 
(IM) injection during a treatment period of 32 days. The 
daily BP-C1 or equal-looking placebo dose was 0.035 mg/
kg bodyweight (BW) or 0.07  mL/kg BW. BP-C1 was sent 
from the hospital to the local medical center, and a nurse gave 
the patients the injections in either the clinic or the patient’s 
home. Clinical and laboratory examinations took place after 
16 and 32 days of treatment designated as Day 16 (16±2 days) 
and Day 32 (33±1 days), respectively. Blood samples for 
Table 1 Baseline characteristics and previous cancer treatments
Factor specifications Controlled clinical 
study
BP-C1 
(N=16)
Placebo 
(N=15)
Demographic 
factors and vital 
signs
age (years) 52.1 (7.2) 56.4 (10.1)
35.6–64.2 35.6–74.3
Duration of 
disease (years)
4.9 (3.2)
1.5–11.2
4.03 (2.2)
1.4–8.8
BMI (kg/m2) 23.0 (3.0) 21.9 (4.8)
17.1–29.3 13.3–30.9
Systolic blood 
pressure (mmHg)
117 (16)
92–140
121 (14)
95–151
Diastolic blood 
pressure (mmHg)
76 (9)
64–93
75 (12)
54–94
Heart rate 
(beats/min)
91 (12) 88 (13)
76–112 62–112
Respiratory rate 
(breath/min)
19.9 (1.1) 20.5 (0.9)
18.0–22.0 20.0–22.0
Previous cancer 
treatment
Surgery 14 14
Hormone 
therapy
8 8
Antibody therapy 0 0
Radiotherapy 13 13
others 0 0
Notes: Assumed continuously distributed factors are expressed by mean value, 
StD in brackets, and total range. The discrete factors are expressed in the number 
of patients.
Abbreviation: BMI, body mass index; StD, standard deviation.
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laboratory examination, CTC-NCI, adverse events (AEs), 
and QLQ were performed and recorded. Thoracoabdominal 
CTs were performed at Day 32, and the patients were clas-
sified as CR, PR, SD, or PD in accordance with the RECIST 
procedure. At the end of the 32-day treatment period, the 
randomization code was broken.
The patients allocated to placebo were crossed-over 
to BP-C1 for an additional 32 days of treatment and were 
followed up as previously described for the first treatment 
period. New CTs of the chest and abdomen and blood samples 
for laboratory examination were taken, and CTC-NCIs, AEs, 
and QLQs were performed and recorded.
Statistical analysis
The main variables in the study are percentage change from 
baseline to final measurement. Distribution analysis was per-
formed by using the Shapiro–Wilk test,19 Daniel half-normal 
plot,20 and trace analysis.21 All continuously distributed main 
variables were unimodal and symmetrically distributed, 
reported as mean values with StD in brackets and 95% CIs, 
and calculated in accordance with the Student’s procedure.22 
Discrete and categorical variables are reported in contingency 
tables.23 Changes in discrete variables are given in switch 
tables. In case of missing observation, the procedure “last 
observation carried forward” was used.24,25
All comparisons between study arms and groups were 
performed two tailed, and differences considered significant 
for P-values ≤5%. Analysis of covariance was performed 
for the comparison of groups with regard to the continuously 
distributed variables with the initial observation and hospital 
site as covariate.26 A contingency table analysis was used 
for a comparison of the groups with regard to discrete and 
categorical variables.23
Ethics approval
Institute for Development of Human Research Protection 
(IHRP),Thailand, June 17, 2013, approved this study.
Results
Tumor growth and RECIST
The sum lesions increased from 53.6 mm (95% CI: 33.5–
73.8) to 55.5 mm (95% CI: 35.4–75.6) in the BP-C1 group 
and from 60.6 mm (95% CI: 35.1–86.1) to 79.1 mm (95% CI: 
46.5–111.7) in the placebo group during the 32 days of treat-
ment (Figure 1). This represents an increase of 8.9% (95% CI: 
–0.1–17.9) and 37.6% (95% CI: 24.3–50.9) in the BP-C1 and 
the placebo groups, respectively. The increase in the placebo 
group was significant (P<0.001) but not in the BP-C1 group. 
The difference between the groups in percentage increase in 
sum lesions was significantly in favor of BP-C1 (P<0.01). 
Twelve of the 15 patients in the placebo group were crossed-
over to 32 days of BP-C1 treatment (Figure 1). The sum 
lesions in this group increased by 35.2% during the placebo 
period and increased from 70.9 mm (95% CI: 35.7–106.2) 
to 71.6 mm (95% CI: 35.9–107.3), representing an increase 
of 3.5% after switching to BP-C1.
A significant difference (P<0.01) was detected in favor of 
BP-C1 regarding the treatment classification in accordance 
with the RECIST criteria (Table 2). Thus, 81.3% were clas-
sified as SD in the BP-C1 group and 33.3% were classified 
as SD in the placebo group. After switching from placebo to 
BP-C1, 91.7% were classified as SD (Table 2). In the joint 
P<0.001
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Figure 1 The development in sum of the largest diameters of target lesions in 
millimeter.
Notes: The results are expressed by mean values with 95% CIs illustrated by col-
umns. The horizontal line crossing the columns shows the mean values. The green 
column shows BP-C1, and the yellow column shows placebo. The blue column 
shows the development in the 12 patients after switching from placebo to BP-C1.
Table 2 Treatment response after 32-day of treatment with BP-
C1 and placebo
Treatment group Day 32 of treatment Total
PD SD
Randomized to BP-C1 3 13 (81.3% [54.3–96.0]) 16
Randomized to placebo 10 5 (33.3% [11.8–61.6]) 15
Placebo group crossed 
over to Bp-C1
1 11 (91.7% [61.5–99.8]) 12
Joint BP-C1 group 4 24 (85.7% [67.3–96.0]) 28
Note: The results expressed as observed numbers with percent responder and 
95% CI.
Abbreviations: PD, progressive disease; SD, stable disease.
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BP-C1 group, 24 of the 28 patients were classified as SD, 
representing 85.7%.
Tolerability
The sum of CTC-NCI score in the BP-C1 group declined 
slightly during the first 16 days, but overall, it increased non-
significantly, with 18.7% from screening to Day 32 (Figure 2). 
In the placebo group, the sum of CTC-NCI score increased 
continuously and significantly (P=0.04) with 50.9% during 
the similar 32 days of treatment. The results were in favor 
of BP-C1, but the difference was not significant (P=0.22). 
The development of the sum CTC-NCI score in the placebo 
patients crossed to BP-C1 followed the same pattern as 
obtained in the patients randomized to BP-C1 and ended 
with a nonsignificant increase of 45.2% from baseline to Day 
32. The sum of CTC-NCI score in the joint BP-C1 group 
increased nonsignificantly with 29.2% during the treatment.
adverse events
A total of 310 mild-to-moderate AEs and 10 severe AEs 
were reported in the BP-C1 group compared to 318 mild-
to-moderate AEs and 29 severe AEs in the placebo group. 
Four mild-to-moderate AEs were classified as “possible” 
or “probably” related to the BP-C1 treatment. Two of 
these were gastrointestinal disorders and two related to the 
injection site. In the placebo group, two mild-to-moderate 
AEs and one severe AE were classified as related to the 
treatment. Of these, one was a gastrointestinal disorder, 
one was injection site related, and one was severe due to an 
increase in ALT. During the study, six serious AEs occurred 
in three patients; all randomized to placebo but were not 
classified as related to treatment. Additionally, one patient 
died after 31 placebo injections, before the planned change 
to BP-C1 treatment.
QOL questionnaires
“Physical activity problems last week” increased nonsig-
nificantly during the 32 days of treatment in both groups. 
A similar pattern was observed for “discomfort last week”. 
This was unchanged the first 16 days but slightly increased 
in both groups at Day 32. The “health and life quality” score 
did not change significantly either within or between the treat-
ment groups. The evolution of these three variables in the 12 
placebo patients changed to BP-C1 treatment after 32 days 
showed the same pattern as recorded in the BP-C1 group.
“Breast cancer problems last week” and “sexual interest 
and activity last 4 weeks” remained unchanged in both groups 
during 32 days treatment (Table 3). “Breast cancer-related pain 
and discomfort last week” was unchanged in the BP-C1 group 
but increased in the placebo group from screening to Day 32.
“Breast cancer treatment problems last week” and “breast 
cancer-related pain and discomfort last week” declined 
after changing from placebo to 32 days of BP-C1 treat-
ment. “Breast cancer-related pain and discomfort” declined 
significantly (P≤0.05) and “sexual interest and activity last 
4 weeks” increased nonsignificantly.
In the joint BP-C1 group, both “breast cancer treatment 
problems last week” and “sexual interest and activity last 
4 weeks” were nearly unchanged from the start of BP-C1 to 
Day 32. The “breast cancer-related pain and discomfort last 
week” score declined nonsignificantly by 2.3% during the 
same treatment.
Tumor growth related to receptor status
The ratio of negative/positive ER was 13/15, that of PtR 
was 15/13, and that of HER2 was 15/13 in the 28 patients of 
the joint BP-C1 treated group (Table 4). The sum of target 
lesion diameters increased significantly in the ER-positive 
group (P=0.02), whereas a nonsignificant reduction (P=0.08) 
was observed in the group with negative ER. The percent-
age change in the sum lesions was in favor of negative ER 
(P=0.12). The sum of diameter in the group with positive PtR 
increased significantly (P=0.03), whereas the negative PtRs 
declined nonsignificantly. The percentage change in sum 
lesions was significantly in favor of negative PtR (P=0.02). 
No significant differences were observed between positive 
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Figure 2 The development in sum of CTC-NCI toxicity score from screening to 
Days 16 and 32 in the BP-C1 group and the placebo group.
Notes: The results are expressed by mean values with 95% CIs illustrated by col-
umns. The horizontal line crossing the columns shows the mean values. The green 
column shows BP-C1, and the yellow column shows placebo.
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and negative HER2 patients. The increase in sum lesions 
was significantly reduced (P=0.03) with increasing number 
of negative receptors (Table 5). In this pooled group of 0–1 
negative receptors, a significant increase of 13.6% (95% CI: 
2.7%–24.5%) in sum of diameters was recorded (P=0.03). The 
group with 2–3 negative receptors showed a reduction in the 
sum lesions of 2.8% (95% CI: –13.2–7.6.2). The percentage 
change in sum lesions was significantly in favor of double- or 
triple-negative receptors (P=0.03).
Discussion
This study has demonstrated that 86% of pretreated women 
with MBC from rural Thailand obtained SD according to the 
RECIST criteria27 after one daily IM injection for 32 days of 
the novel platinum compound BP-C1. The efficacy of BP-C1 
increased parallel to the number of negative ER, PtR, and 
HER2 receptor, and both the QOL and toxicity were more 
favorable compared to the placebo. Only few and mild-to-
moderate AEs were registered as probably related to BP-C1 
treatment.
The first clinically approved and best-studied platinum 
compound was cisplatin,28 and the second approved was carbo-
platin.29 Numerous studies of platinum compounds’ synthesis 
and efficacy have been conducted, but insufficient selectivity 
for malignant cells, severe side effects, and drug resistance 
are still characteristic features of these drugs.30,31 BP-C1 was 
Table 3 Comparison between groups and development within groups with regard to the sum of scores within each of the three parts 
in questionnaires QLQ-BR23CIs
Variables Treatments Screening Day 16 of 
treatment
Day 32 of 
treatment
Increase
(day 32-screening)
Breast cancer treatment 
problems last week
Bp-C1 (n=16) 16.1 (3.6) 14.3 (4.6) 16.5 (3.2) 0.4 (2.8)
14.1–18.0 11.8–16.8 14.8–18.2 –1.0 to 1.9
Placebo (N=15) 15.3 (2.3) 15.3 (2.4) 15.3 (2.5) 0.1 (3.2)
14.0–16.5 13.9–16.6 14.0–16.7 –1.7 to 1.8
Sexual interest and 
activity last 4 weeks
Bp-C1 (n=16) 3.1 (1.8) 2.8 (1.8) 2.8 (1.6) –0.4 (1.5)
2.2–4.1 1.9–3.8 1.9–3.6 –1.2 to 0.4
Placebo (N=15) 3.4 (2.1) 2.7 (1.6) 2.2 (0.6) –1.2 (2.1)
2.3–4.5 1.9–3.6 1.9–2.5 –2.4 to –0.1
Breast cancer-related pain 
and discomfort last week
Bp-C1 (n=16) 11.1 (4.1) 10.0 (4.0) 11.3 (4.6) 0.2 (2.1)
8.9–13.3 7.4–12.6 8.9–13.7 –0.9 to 1.3
Placebo (N=15) 9.6 (1.9) 10.0 (3.0) 10.5 (4.1) 0.9 (2.9)
8.5–10.7 8.3–11.7 8.3–12.8 –0.7 to 2.5
Note: The results expressed as mean values with 95% CIs and StD in brackets.
Abbreviation: StD, standard deviation.
Table 4 “Negative” and “positive” ER, PR, and HER2 comparison with regard the development in the sum of target diameter lesions
Receptors Classification Sum lesion diameter P-value
Baseline Day 32 % (Day 32 
to baseline)
er Negative (n=13) 56.5 (38.9)
32.9–80.0
54.9 (39.6)
31.0–78.9
−0.4 (20.9)
−12.9 to 12.3
0.12
Positive (n=15) 58.2 (54.7)
27.9–88,5
61.3 (54.3)
31.2–91.4
11.4 (18.3)
1.3–21.6
ptr Negative (n=15) 66.3 (43.1)
42.4–90.1 
65.6 (46.3)
39.9–91.3
−2.0 (16.2)
−11.0 to 6.9
0.02
Positive (n=13) 42.2 (51.3)
16.1–78.2
49.9 (48.9)
20.4–79.4
15.2 (20.7)
2.6–27.7
Her2 Negative (n=15) 60.8 (52.5)
31.7–89.9
62.4 (53.4)
32.5–91.7
4.3 (13.0)
−2.9 to 11.4
0.64
Positive (n=13) 53.5 (42.0)
28.1–78.8
53.9 (40.8)
29.2–78.6
7.9 (26.5)
−8.1 to 24.0
Note: The results expressed by mean values, StD in brackets, and 95% CIs.
Abbreviations: ER, estrogen receptor; HER2, human EGF receptor 2; PtR, progesterone receptor; StD, standard deviation.
 
Br
ea
st
 C
an
ce
r: 
Ta
rg
et
s 
an
d 
Th
er
ap
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
5.
17
8.
2 
on
 1
6-
No
v-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Breast Cancer - Targets and Therapy 2019:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
49
BP-C1 in treatment of metastatic breast cancer stage IV
developed for the treatment of MBC and pancreatic cancer. 
The safety and efficacy of cisplatin, carboplatin, and BP-C1 
have been compared in mice with Ehrlich tumors.32 The three 
drugs stimulated apoptosis in tumor tissue, and the specific 
activity of BP-C1 was similar to that of an equimolar dose 
of carboplatin but with lower toxicity. The specific activity 
was lower compared to cisplatin, but significantly superior 
in terms of toxicity, accumulation of bound platinum, and 
duration of antitumor effect. The pharmacokinetic profile in 
dogs follows a two-compartment model with rapid absorption, 
short distribution, a slow elimination phase, and an overall 
elimination half-life of 125 hours.33 BP-C1 is a category 2 
anticancer drug34 and can be safely administrated continuously 
for 32 days.14 The daily maximum tolerated dose (MTD) is 
>0.035 mg/kg, and the minimum efficient dose is estimated to 
0.03 mg/kg. Based on the MTD, BP-C1 is therefore injected 
IM once daily in a dose of 1.12 mg/kg/32 or 0.035 mg/kg. In 
addition to being cytostatic, BP-C1 has immunomodulatory 
properties.35 Thus, activation of monocytes leads to two major 
effects – production of cytokines that are able to increase 
antitumor activity of lymphocytes, and monocytes will acquire 
the ability to inhibit tumor cell growth. In addition, BP-C1 
directly effects lymphocytes, exemplified by the induction of 
IL-25. Finally, BP-C1 has a favorable toxicity profile14,16 and 
exerts a positive effect on hematological and biochemical 
imbalances in patients with MBC.36
The present study confirmed our previously published 
results from two international multicentre studies in pre-
treated MBC patients.14,16 Thus, short-term BP-C1 treatment 
reduced tumor growth, was well tolerated, improved the QOL, 
and had few and mainly mild AEs. Most of the patients in our 
study were recruited from the countryside or small county 
cities. Such patient populations are closely interconnected 
to relatives, neighbors, and the neighborhood. When moving 
such patients to the hospital far away from the neighborhood, 
their QOL is significantly reduced. A well-equipped and clean 
hospital with good clinical support and optimal medical 
treatment is not sufficient to make up for this loss. A major 
advantage of BP-C1 is therefore that it can be administered 
in the home of the patient and, at the same time, they can 
avoid meeting and receiving treatment from different caregiv-
ers. In the present study, BP-C1 was sent from the hospital 
to the local medical center, and a nurse gave the patients 
the injections either in the clinic or in the patient’s home. 
It is uncertain if these pretreated MBC patients could have 
completed systemic chemotherapy far from their home, and 
it would, in all circumstances, have been costly for them.
In the subset analysis, we found that the sum of target 
lesions increased significantly in ER+ and PtR+ patients in 
spite of BP-C1 treatment, whereas the sum of target lesions 
decreased, however, insignificantly, in hormone receptor-neg-
ative patients. These findings correlate with the established 
effects of the receptors, although it is somewhat surprising 
that HER2 expression did not influence the effects of BP-C1. 
Perhaps this finding reflects that hormone receptor-positive 
and hormone receptor-negative tumors in HER2-positive 
breast cancer show distinct histopathological features that 
may be relevant to their clinical behaviour.34 TNBC com-
prised many different disease entities8 and accounts for 
10%–20% of all cases. Convenient treatments used for MBC 
that target these receptors are not effective for TNBC, and 
chemotherapy is still the primary systemic treatment for 
Table 5 Comparison of number of negative receptors with regard the development in the sum of target diameter lesionsCIs
Number of 
negative receptors
Sum lesion diameter P-value
Baseline Day 32 % (Day 32 to 
baseline)
0 negative
receptors (n=3)
34.3 (31.8)
−44.7 to 113.4
40.7 (31.4)
−37.3 to 118.6
29.3 (32.5)
−51.5 to 110.2
0.03
1 negative
receptor (n=12)
53.8 (53.9)
19.6 to 88.1
55.8 (52.3)
22.6 to 89.0
9.7 (14.7)
0.3 to 19.0
2 negative
receptors (n=8)
72.5 (52.4)
28.7 to 116.3
70.4 (55.0)
24.4 to 116.3
−3.0 (20.3)
−20.0 to 14.0
3 negative
receptors (n=5)
55.6 (28.6)
20.0 to 91.2
55.6 (35.5)
11.5 to 99.7
−2.6 (13.0)
−18.8 to 13.5
0 or 1 negative 
receptor (n=15)
49.0 (50.0)
22.3 to 77.6
52.8 (48.2)
26.1 to 79.5
13.6 (19.7)
2.7 to 24.5
0.032 or 3 negative 
receptors (n=13)
66.0 (44.1)
39.3 to 92.7
64.7 (47.3)
36.1 to 93.3
−2.8 (17.3)
−13.3 to 7.6
Note: The results expressed by mean values, StD in brackets, and 95% CIs.
Abbreviation: StD, standard deviation.
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TNBC patients in both the early and metastatic stages of 
the disease. However, the outcome is, overall, poor in triple-
negative MBC and novel treatment strategies are highly 
desirable. So far, anthracyclins, taxanes, and carboplatin as 
single agents or in combination with other treatments are 
frequently used, but toxicity that necessitates delays dose 
reduction or ending the treatment is a common side effect. 
In the present study, we observed that the efficacy of BP-C1 
treatment increased with the number of negative receptors. 
Only four mild-to-moderate AEs were considered as related 
to BP-C1 treatment, and the QOL was maintained during 
the treatment.
Conclusion
BP-C1, due to its efficacy, very few side effects, maintain-
ing the QOL and patient-friendly and cost-effective way of 
administration, may be an important novel compound for 
the treatment of MBC and, in particular, the triple-negative 
subgroup of these patients. The next steps should be studies 
of BP-C1 monotherapy continued until disease progression; 
refinement of receptor results in a larger patient sample and 
analyses of the outcome of combination treatment of BP-C1 
with other anticancer drugs.
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